Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

IONS

Kedudukan dalam Saham #2584
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Harga Saham
$44.47
Modal Pasaran
$7.39B
Perubahan (1 hari)
0.20%
Perubahan (1 tahun)
-39.54%
Negara
US
Perdagangan Ionis Pharmaceuticals, Inc. (IONS)

Kategori

Healthcare
Bilangan saham terbitan bagi Ionis Pharmaceuticals, Inc. (IONS)
Bilangan saham terbitan setakat June 2026: 165.42M
Menurut laporan kewangan terkini dan harga saham Ionis Pharmaceuticals, Inc., bilangan saham terbitan semasa ialah 165.42M. Pada akhir December 2023, syarikat mempunyai 143.00M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Ionis Pharmaceuticals, Inc. (IONS) dari 2000 hingga 2026
Saham terbitan pada akhir setiap tahun
Tahun Saham Terbitan Ubah
2026 (TTM) 165.42M 10.64%
2024 149.51M 4.56%
2023 143.00M 0.81%
2022 141.85M 0.59%
2021 141.02M 1.01%
2020 139.61M -0.28%
2019 140.00M 5.80%
2018 132.32M 6.70%
2017 124.02M 2.66%
2016 120.80M 1.26%
2015 119.29M 1.36%
2014 117.69M 6.51%
2013 110.50M 9.87%
2012 100.58M 0.92%
2011 99.66M 0.52%
2010 99.14M 1.05%
2009 98.11M 3.75%
2008 94.57M 12.93%
2007 83.74M 12.69%
2006 74.31M 18.18%
2005 62.88M 11.01%
2004 56.64M 2.13%
2003 55.46M 1.80%
2002 54.48M 23.51%
2001 44.11M 19.14%
2000 37.02M 0.00%
Saham terbitan bagi syarikat atau pesaing yang serupa
Syarikat Saham Terbitan Perbezaan Negara
253.90M 53.49%
US
396.00M 139.39%
US
478.91M 189.51%
AU
- -
CH
62.19M -62.41%
NL